1. Radio-frequency identification (RFID) tag localisation of non-palpable breast lesions a single centre experience.
- Author
-
Almalki, Hend, Rankin, Adeline C., Juette, Arne, and Youssef, MinaM.G.
- Subjects
RADIO frequency identification systems ,NEOADJUVANT chemotherapy ,CANCER invasiveness ,SURGICAL excision ,BREAST cancer ,CALCIFICATION - Abstract
The purpose of this study is to report the surgical experience and outcomes with pre-operative localisation of non-palpable breast lesions using the RFID tag system. The cohort for this prospective study included patients over the age of 18 with biopsy proven, non-palpable indeterminate lesions, DCIS or breast cancer requiring pre-operative localisation before surgical excision between September 2020 and July 2022. A total of 312 RFID tags were placed in 299 consecutive patients. Indications for localisation included non-palpable invasive cancer in 255 (85.3%) patients, in situ disease in 38 (12.7%) and indeterminate lesions requiring surgical excision in 6 (2.0%). Both in situ and invasive lesions had a median size of 13 mm (range 4–100 mm) on pre-operative imaging. The RFID tags were in situ for a median time of 21 days before surgery (range 0–233 days). Of the 213 tags, 292 (93.6%) were introduced using ultrasound (USS) guidance and stereotactically in 20 (6.4%). In 3 (1.0%) cases the RFID tag was either not satisfactorily deployed at the intended target or retrieved intra-operatively. Following discussion of post-operative histology by the multi-disciplinary team, further surgery for close or involved margins was for 26 (8.7%) patients. The Hologic RFID tag system can be used for accurate pre-operative localisation of non-palpable masses as well as diffuse abnormalities such as mammographic distortions and calcifications. It has advantages of flexibility for scheduling image-guided insertion independently of scheduled operating lists and can be placed to localise lesions prior to initiating neoadjuvant systemic treatment. • RFID tag localisation of non-palpable malignant and indeterminate lesions is accurate and oncologically safe. • Insertion by ultrasound or sterotactic guidance uses visible tumour, calcification or a hydroclip as the target. • In 99% of cases the RFID tag was satisfactorily deployed at the intended target and retrieved intra-operatively. • The rate of re-operation for close or involved margins was 8.6%. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF